The $35 million investment will more than double the site’s batch-size scaling and product output.

Curia has announced it plans to invest more than $35 million in expanding its commercial API manufacturing capacity at its Rensselaer, New York facility.

The CDMO, which was formerly known as AMRI, has said the increased production capacity and product-handling solutions will strengthen its ability to manufacture small-scale to large-volume complex APIs for its current and future partners.

The $35 million investment will include new vessel capacities that more than double the site’s batch-size scaling and product output. It will also allow for the introduction of a variety of new products and enable Curia to meet growing demand for high potency API manufacturing.

Curia Chairman and CEO John Ratliff said: "The engineering and technology advances we have designed for the site will enhance our flexibility, efficiency and scale, allowing us to meet our customers’ current and future complex manufacturing needs.”

Integral to the expansion are plans to optimise energy usage and enhance environmental standards.

Curia’s Rensselaer facility currently produces APIs to meet the development and commercial needs of more than 50 products, including critical oncology therapeutics and novel treatments addressing unmet medical needs.

Last year, it was the first facility in the industry to be designated 'Industry Leader' as part of its re-certification under the independent SafeBridge program for “Potent Compound Safety Certification”.

The expansion is expected to be completed within 18 months and generate new technical jobs in Rensselaer.